Exosomes as emerging biomarkers in breast, lung, and colorectal cancer diagnosis: A comprehensive review.
Blood-based exosome signatures could enable simpler, earlier detection of breast, lung, and colorectal cancers alongside standard tests.
This review systematically appraises clinically advanced exosomal biomarkers for non-invasive early detection across three major solid tumor types—breast, lung, and colorectal cancer—highlighting validated signatures with high diagnostic performance relative to current standards. The authors recommend multi-omic exosomal panels integrated with clinical data as triage adjuncts, with particular promise for tissue-free molecular subtyping and premalignant lesion detection.
What the study was
- Study design
- Systematic/narrative review
- Population
- Patients with breast, lung, and colorectal cancers
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Seminars in Oncology
Why it surfaced
Review focuses on translationally ready exosomal biomarkers with validated diagnostic performance for three high-burden cancers; EARLY_CANCER_DETECTION flag upgrades to HIGH priority per pipeline rules. Multi-omic integration emphasis adds near-term implementable value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.